Vivos Therapeutics (VVOS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Vivos Therapeutics (VVOS) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.16 of bullish evidence against -0.43 bearish.

Vivos Therapeutics last closed at $0.15, +0.00% on the session.

Against the IVW growth benchmark the position is -0.80% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for VVOS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Vivos Therapeutics in the 100th percentile on return on equity, where 100 is best.

Vivos Therapeutics is classified under Health Care / Health Care Providers & Services, with a market capitalisation of $5.02M.

StockMap tracks Vivos Therapeutics as the 85th largest of the 85 companies it covers in the Health Care Providers & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 81 Neutral and 4 Moderate Underperform.

On that composite Vivos Therapeutics ranks 84th of 85 in the group, against a group median of +0.00.